Many clinical trials utilizing checkpoint inhibitors in ovarian cancer patients concluded that the expression of PD-L1 in ovarian cancer cells, the histotype, and previous treatment are associated with the success of immune therapies. The gene discussed is CD274; the disease is ovarian cancer.